As the number of asthmatics, COPD, and allergy patients continues to grow, the upper respiratory treatment market is attracting a number of new companies – companies with some novel approaches to the problem of chronic airway inflammation. These companies are conducting ongoing........more

Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions – aliments that require  .......more

The convergence of socioeconomic and technology factors – the growing emphasis on drug self-administration for chronic conditions, the expected acceleration in protein- and peptide-based therapeutics, the availability of innovative dry powder inhalation devices with unique .......more